title: Nucleic acid aptamers for target validation and therapeutic applications.
abstract: In the simplest view, aptamers can be thought of as nucleic acid analogs to antibodies. They are able to bind specifically to proteins, and, in many cases, that binding leads to a modulation of protein activity. New aptamers are rapidly generated through the SELEX (Systematic Evolution of Ligands by Exponential enrichment) process and have a very high target affinity and specificity (picomoles to nanomoles). Furthermore, aptamers composed of modified nucleotides have a long in vivo half-life (hours to days), are nontoxic and nonimmunogenic, and are easily produced using standard nucleic acid synthesis methods. These properties make aptamers ideal for target validation and as a new class of therapeutics. As a target validation tool, aptamers provide important information that complements that provided by other methods. For example, siRNA is widely used to demonstrate that protein knock-out in a cellular assay can lead to a biological effect. Aptamers extend that information by showing that the dose-dependent modulation of protein activity can be used to derive a therapeutic benefit. That is, aptamers can be used to demonstrate that the protein is a good target for drug development. As a new class of therapeutics, aptamers bridge the gap between small molecules and biologics. Like biologics, biologically active aptamers are rapidly discovered, have no class-specific toxicity, and are adept at disrupting protein-protein interaction. Like small molecules, aptamers can be rationally engineered and optimized, are nonimmunogenic, and are produced by scalable chemical procedures at moderate cost. As such, aptamers are emerging as an important source of new therapeutic molecules.
authors.affiliation: Archemix Corp., 1 Hampshire Street, Cambridge, MA 02139, USA. pendergrast@archemix.com
authors.forename: P Shannon
authors.initials: PS
authors.lastname: Pendergrast
authors.forename: H Nicholas
authors.initials: HN
authors.lastname: Marsh
authors.forename: Dilara
authors.initials: D
authors.lastname: Grate
authors.forename: Judith M
authors.initials: JM
authors.lastname: Healy
authors.forename: Martin
authors.initials: M
authors.lastname: Stanton
mesh_terms: D000818:Animals; D000991:Antithrombins / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D016527:Drug Costs; D009696:Nucleic Acids / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000991:Antithrombins; D009696:Nucleic Acids; D010982:Platelet-Derived Growth Factor; D042461:Vascular Endothelial Growth Factor A